learn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
Search
forLearn
5 / 801 resultslearn orange
learn oleanolic acid
learn pyrrolidone carboxylic acid
learn enoxolone
Research
5 / 363 results
research Acneiform Rash Caused by an Unlikely Drug: Topiramate
A man got a rare rash from the drug topiramate, which went away after he stopped taking it.
research Hot Flashes in a Young Girl: A Wake-up Call Concerning Serenoa repens Use in Children
Serenoa repens (saw palmetto) may cause side effects like hot flashes in children and needs more research for safety in pediatric use.
research Mirtazapine-induced Gynecomastia: An Unknown Side Effect?
Mirtazapine can cause male breast enlargement.
research HAIR LOSS ASSOCIATED WITH ESCITALOPRAM: DO SSRIs AFFECT MELATONIN AT THE HAIR FOLLICLE?
The antidepressant escitalopram likely caused hair loss in a patient.
research Alopecia associated with agomelatine use: a case report
Stopping the antidepressant agomelatine improved hair loss in a patient.
Community Join
5 / 1000+ resultscommunity Extreme caution: my experience using Ru58841 only once
An 18-year-old experienced severe side effects, including heart palpitations and high blood pressure, after using RU58841 once, leading to a referral to cardiology for suspected left ventricular hypertrophy. The user regrets using RU58841 and seeks advice on recovery, while others suggest preexisting conditions or genetic predispositions may be factors.
community Doubtful of RU58441's negative effects
RU58841's potential side effects, particularly heart palpitations, are debated, with some attributing them to contamination with minoxidil. Users report mixed experiences, with some seeing no side effects and others cautioning about the lack of reliable data on RU58841's safety.
community Why are there no proper phase 3 trials for RU
RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.
community Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
community PP405 2a study was a safety study. Some rational explaining.
The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.